Clinical Trials
16
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Comparison of Noninvasive Vs. Invasive Hemodynamic Measurements
- Conditions
- Heart Failure, Congestive
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Nihon Kohden
- Target Recruit Count
- 30
- Registration Number
- NCT06689215
- Locations
- 🇺🇸
Stanford University Hospital, Stanford, California, United States
Accuracy of Pulse Oximeters With Profound Hypoxia At Rest (NIHO18)
- Conditions
- Hypoxia
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Nihon Kohden
- Target Recruit Count
- 13
- Registration Number
- NCT05807464
- Locations
- 🇺🇸
UCSF Hypoxia Research Laboratory, San Francisco, California, United States
Accuracy of Pulse Oximeters With Profound Hypoxia At Rest (NIHO19)
- Conditions
- Hypoxia
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Nihon Kohden
- Target Recruit Count
- 13
- Registration Number
- NCT05807477
- Locations
- 🇺🇸
UCSF Hypoxia Research Laboratory, San Francisco, California, United States
Accuracy of Pulse Oximeters With Profound Hypoxia At Rest (NIHO16)
- Conditions
- Hypoxia
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Nihon Kohden
- Target Recruit Count
- 11
- Registration Number
- NCT05745675
- Locations
- 🇺🇸
UCSF Hypoxia Research Laboratory, San Francisco, California, United States
Accuracy of Pulse Oximeters With Profound Hypoxia At Rest (NIHO17)
- Conditions
- Hypoxia
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Nihon Kohden
- Target Recruit Count
- 11
- Registration Number
- NCT05745662
- Locations
- 🇺🇸
UCSF Hypoxia Research Laboratory, San Francisco, California, United States
- Prev
- 1
- 2
- 3
- Next
News
FDA Clears Ceribell's AI Algorithm for Pediatric Seizure Detection in Patients as Young as One Year Old
Ceribell has received FDA 510(k) clearance for its next-generation Clarity algorithm that can detect electrographic seizures in patients as young as one year old, becoming the first AI-powered point-of-care EEG system with this capability.